PMD127 Medical Devices: Innovative Models To Access The Market Leveraging On Shared Infrastructure Among Payers And Pharmaceutical Companies  by Ortali, M et al.
A366  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
focusing on medical devices is currently in development, with the clarification of 
CD’s status expected. However, there is a gap between institutional and scientific 
timelines given that scientific research is already going a step further with the high-
throughput DNA sequencing which would need to be rewarded as well.
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Objectives: Introducing ‘Selective reimbursement scheme’ and reviewing what 
kinds of medical services were involved in plan to strengthen the NHI coverage 
for the four major diseases in 2014. MethOds: The MOHW has been reducing 
the patient’s co-payment ratio to 50~ 80% from 100% for non-reimbursed medical 
services that have large demand for the NHI coverage but the cost-effectiveness 
is low since 2014. A medical service for cosmetic purposes is supposed to be non-
reimbursement category. Once a service or product was assigned to selective reim-
bursed category, reimbursement ratios are determined in 50% or 80% based on the 
evaluation criteria which has 3 aspects of ‘Clinical Usefulness’, ‘Cost Effectiveness’, 
‘Social Demand of Reimbursement’. Results: Based on the evaluation criteria for 
‘Selective reimbursement’, total 12 items were assessed and enlisted in selective 
reimbursement category. This plan benefits 842 thousand patients and reduced 
non-reimbursement cost to 577 million(2014) from 1,119 million(2012) related to 
the four major diseases. cOnclusiOns: NHI coverage is extremely focused on 
the four major diseases and this will cause discrimination against other diseases. 
In terms of patients’ aspect, it may be asked whether this plan is effective to give 
patients an advantage enough to feel under 80% co-payment ratio. The decision 
making process and medical devices price appraisal remains to be considered as 
its transparency and rationality.
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Objectives: Our objective was to estimate the impact of availability of new endo-
vascular therapies on treatment volumes for femoropopliteal arterial disease in 
the German health care system. Germany was among the first markets to adopt 
and reimburse new endovascular techniques including drug-coated balloons 
(DCB), drug-eluting stents (DES), and latest atherectomy devices. MethOds: We 
collected therapy-specific procedure volumes for the 5-year period 2009-2013 from 
the German Federal Statistics Office for plain balloon angioplasty (PTA), DCB, BMS, 
DES, and atherectomy. In addition, surgical bypass and relevant amputation pro-
cedure volumes were collected. To assess general changes in hospitalization vol-
umes of patients with primary diagnosis of peripheral artery disease (PAD), we also 
obtained ICD-10-specific discharge information. We evaluated the 5-year growth for 
each of the studied treatment modalities, and analyzed their relative utilization 
level in the latest reported year, 2013. Results: Endovascular procedure volumes 
grew from 73,927 in 2009 to 98,730 in 2013 (+34%), while bypass surgery volumes 
decreased from 31,970 to 29,042 (-9%), for a combined growth of 21% in total pro-
cedure volumes. Hospitalizations with primary diagnosis of PAD increased by 11% 
in this period (168,845 to 187,563). At the same time, lower extremity amputations 
remained stable (+1.6%). However, a substantial shift from major to minor amputa-
tions could be observed (-14.5%; +10.5%). In 2013, PTA, DCB, BMS, DES, and atherec-
tomy constituted 51.6%, 16.3%, 28.0%, 0.9%, and 3.2% of the total endovascular case 
volume. DCBs exhibited the most rapid growth, with their relative share of endovas-
cular interventions increasing from 6.2% in 2009 to 16.3% in 2013. cOnclusiOns: 
Five-year national data from the German healthcare system demonstrate that the 
availability of new endovascular therapies has led to substantial growth in femo-
ropopliteal arterial disease procedure volumes, expanding the treated population 
and partially replacing surgical bypass treatment. Concurrently, our results suggest 
a trend towards improved limb salvage.
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MeDiCal DeviCes: iNNovative MoDels to aCCess the MaRKet 
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CINECA Interuniversity Consortium, Casalecchio di Reno, Italy
Objectives: To provide on-line shared infrastructures among Payers and 
Companies, used by health personnel, regulatory bodies and Sponsors, in order 
to allow the management of medical devices delivery process, from prescription 
until direct reimbursement from National Health System. MethOds: Based on a 
long history in collecting and analyzing real-world data, CINECA Interuniversity 
Consortium has developed an innovative Cloud-based IT infrastructure for the 
entire management of the service arrangements among Pharmaceutical Companies 
and Payers. The solution is designed to ensure proper data collection aimed to 
evaluate appropriateness, assess device performance and estimate efficacy in a 
real-world context, according to highest quality and security industry standards. The 
system may foresee the direct distribution of device and materials to the patient, 
in order to speed up the process and increase compliance. Results: In innovative 
therapies setting, the web-based system has been used in Italy for more than 75.000 
patients with type 2 diabetes treated with antidiabetic drugs. Access to therapy was 
allowed through 3.741 diabetes specialists belonging to 1.278 dedicated centers. The 
system is being extended to manage and allow market access for innovative devices. 
The system can manage the entire process of device management (prescription, 
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Objectives: The use of medical images has become a great tool that enables a 
rapid diagnosis, aids in taking relevant decisions early in the process, facilitates 
the formulation of a second opinion in cases of doubt. Solid tumors are very rare in 
children and individual clinician experience is often quite limited. Yet the treatment 
decisions which must be made can be complex and diagnostic dilemmas are com-
mon. MethOds: Supported by a grant from EU-funded Project ENCCA (European 
Network for Cancer Research in Children and Adolescents), representatives from 
SIOPEL, GPOH, COG, and JPLT developed the Virtual Consultation System. VCS is a 
novel tool developed by Cineca Interuniversity Consortium to support clinical chal-
lenges in management of complex cases, which require the consultation among 
experts coming from different hospitals or countries. VCS allows to assess complex 
cases using relevant medical information from structured data (e-CRFs) and diag-
nostic DICOM images. VCS can be customized according to specific requirements 
in all of its components such as user roles, process flows, and the input and output 
information (i.e. e-CRFs, images, consensus form) linked to the different tasks in 
the review process. Results: The main output is a report containing the collec-
tive findings, conclusions and recommendations for the further treatment of the 
patient. The use of a web-based consultation system is an essential component 
of excellence in diseases care because it enables patients to have access to the 
best available global expertise. This tool is particular important for rare tumors 
where clinicians need to get consultation from other colleagues in different areas 
of the world. cOnclusiOns: This consultation service represents an opportunity 
to enhance the care of children with rare tumors and facilitates education of clini-
cians caring for such challenging patients. Such a consultation service may serve 
as a model for cooperative management of other rare malignancies.
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Objectives: A clinical pathway is defined as the succession of medical events 
that jointly aim at improving the patients’ condition. It provides efficient care by 
standardizing processes, reducing the variability of practices and improving the out-
comes. Hospital Information Systems contain valuable data about these pathways. 
However, they are hardly tapped due to their volume and complexity. The objective 
of the study is to factually describe the clinical pathways of patients implanted with 
a CRT defibrillator (CRT-D) on an 8 years timeline from the French PMSI database. 
The PMSI annually includes the records of all hospital stays in the country. This 
description will bring new knowledge about the patients care to find out the correla-
tions with their condition. MethOds: From the 2008 database in public hospitals, 
we extracted all hospital stays with an implantation of a CRT-D in France, leading to 
1,602 patients. The patient’s anonymous identifiers were used to find all their hos-
pital stays during the 2 previous years (2006-2008) and the 5 following years (2008-
2013), being a total of 16,931 stays. These data were analyzed using Process Mining 
methods to find similarities in the patient’s sequences of stays. We also developed 
a specific visualization tool to illustrate the results. Results: We quantified the 
hospitalization risks on a long-term follow-up: hospitalization for heart failure was 
observed 3 months prior to implantation in 51% of patients, and 8 months after 
implantation in 50%. 28% of patients were readmitted for the device’s replacement 
after 2 years and 2 months, and 20% died at the hospital within 5 years. These risks 
were also assessed depending on the patient’s comorbidities. cOnclusiOns: This 
study shows that Process Mining methods are relevant to analyze clinical pathways 
at a national scale from big sized database. This descriptive approach is the prereq-
uisite for predictive analytics.
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Objectives: Targeted therapies have a growing place within the therapeutic land-
scape and represent an innovative sector. Companion diagnostics (CD) are com-
plementary to targeted therapies; however there is an unbalanced environment 
between both technologies with limited incentive measures to support the develop-
ment of diagnostic tests. The aim of this analysis was to review and compare the 
existing processes in Europe and North America, and see how CD benefits could 
be rewarded. MethOds: An analysis was performed of the healthcare systems 
in France, the United Kingdom, Germany and the United-States. Advantages and 
disadvantages of country-specific pricing and reimbursement policies were high-
lighted. A literature review was then conducted to identify the benefits related to CD 
and potential processes to capture these benefits. Searches were run on electronic 
databases (i.e. MEDLINE and MEDLINE In-Process) and were supplemented by hand 
searches to ensure that most relevant publications were included. Results: The 
analysis of healthcare systems showed a lack of incentive measures to support the 
development and market access of CD. Benefits associated with CD can be grouped 
into two categories: the health benefits (e.g. prediction of the patient’s response) and 
the economic benefits (e.g. cost-saving due to decrease in the delay of response). To 
reward these benefits, several potential strategies were identified (e.g. intellectual 
property, reform of commissions) and the most reported one being the value-based 
pricing approach. cOnclusiOns: Value-based pricing approaches were widely 
reported to reward the benefits associated with CD. Moreover, a European Directive 
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the Committee for technologies that ultimately did not receive positive endorse-
ment due to clinical benefit or cost considerations. cOnclusiOns: The MTEP is 
the most commonly used process to assess routed technologies and the major-
ity of MTEP evaluations have resulted in positive endorsement. The MTEP process 
assigns equal prominence to healthcare system and patient benefits, with decisions 
being based on the full body evidence available for a technology. However, where 
evidence of clinical effectiveness was associated with uncertainty, the influence of 
demonstrated healthcare system benefits appeared to have limited effect on final 
decision-making.
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Objectives: To describe the use of self-monitoring of blood glucose (SMBG) in a 
cohort of newly treated T2DM subjects and to assess the contribution of SMBG on 
overall antidiabetic and cardiovascular disease prescription costs. MethOds: A 
population based retrospective cohort study was conducted using the Irish national 
pharmacy claims database. Newly treated T2DM patients were identified for 2012 
as being initiated on oral antidiabetic monotherapy and having received no anti-
diabetic therapy in the previous year. Subjects were followed for one year post 
treatment initiation. The association between prescription costs and SMBG was 
assessed using generalised linear model with gamma family and log link functions 
to handle the right skew of the data adjusting for various demographic and treat-
ment factors. Cost ratios and 95% CIs were obtained from this analysis and were 
used to determine the contribution of SMBG to prescription costs. Results: A total 
of 12,941subjects were eligible for the study with 64% of subjects using SMBG. SMBG 
use was highest in subjects aged 40-49 years (71%) and decreased with age, with 
48% of subjects aged 80-89 years using SMBG. Most subjects used SMBG greater than 
once a week but less than daily (41%) or daily and more frequently (51%). Use of 
SMBG resulted in dispensing costs that were overall 81% higher than those without 
SMBG use (95% CI 1.76, 1.92). cOnclusiOns: Use of SMBG in newly treated T2DM 
was high including the frequency of use and resulted in high associated costs. 
SMBG represents a significant financial component in diabetes care, yet previous 
work has shown no clear benefit in newly treated type 2 diabetes patients on oral 
therapy. There is the potential for cost savings by introducing a review or limit on 
the amount of SMBG tests available to newly treated T2DM patients.
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Objectives: The objective of this research is to provide an overview of the regu-
latory process of medical devices market access in Egypt and Saudi Arabia. The 
research paper identifies regulatory institutions, processes, and policy framework 
of the national medical devices policy agenda of Egypt and Saudi Arabia respec-
tively. MethOds: A systematic search of the literature for medical device regula-
tory information was performed, in academic journals and in relevant regulatory 
authorities’ data sources (Egyptian Drug Authority and Saudi FDA web portals). The 
following databases were searched: PubMed (Medline), Science Direct (EMBASE), 
Scopus and the Arabic database Al Manhal. The search methodology employed was 
in line with PRISMA guidelines. The search language was limited to English and 
Arabic. Results: In total, 41 records were included in the qualitative synthesis 
of this review. The governance, process and implementation of medical devices 
market access have been analyzed in detail. The policy framework of both countries 
is adopted from the International Medical Device Regulatory forum and certain 
reference countries. Concerning products’ technical requirements, direct testing 
of medical devices is not required. However, documentary evidence of a medical 
device’s authorization to be sold in a reference country is mandatory. Challenges 
are related to the interim nature of medical devices legislation in both countries, 
presence of a considerable degree of corruption. In addition there is a lack of trans-
parency and electronic databases, especially in Egypt. cOnclusiOns: In both Saudi 
Arabia and Egypt, medical devices market access is straightforward if there is proof 
of authorization to sell a product in a reference country. However, this system has 
disadvantages in terms of safeguarding patient safety and enabling fast access of 
innovations. Lack of transparency, incomplete regulations, corruption, and a lack of 
comprehensive policy for medical devices are challenges faced by both countries.
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Objectives: Hospital acquired infections (HAIs) can have a serious impact on 
both clinical and economic outcomes. As a result, hospitals implement infec-
tion control (IC) policies to prevent and reduce the transmission of HAIs includ-
ing various approaches to screening and testing incoming or admitted patients. 
Early identification of HAIs is key to limiting their clinical and economic impact. 
Molecular diagnostics (MDx) have the potential to improve IC strategies by quickly 
and accurately identifying patients with suspected or confirmed infections. To 
increase adoption of this technology, both MDx manufacturers and hospital qual-
ity stakeholders have expressed interest in value-based contracting for HAI tests. 
eligibility, order, delivery and invoicing) in an integrated manner in order to easily 
activate new market opportunities from the perspective of Companies, Payers and 
Patients. By defining appropriate minimum datasets, it is possible to involve all 
stakeholders obtaining systematic, homogeneous and high-quality real-world data 
on the use and appropriateness of such devices. cOnclusiOns: The introduction of 
online integrated and shared infrastructures allows to activate common processes 
among Payers and Companies in the challenge of introducing innovative therapies 
and devices in a strained macroeconomic scenario, with the aim to simplify market 
access, facilitate transparency, monitor related costs, while enabling the collection 
of Healthcare Big Data for scientific purposes.
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Objectives: Affixing a CE mark to a product means that the manufacturer is 
declaring that the product meets all legal requirements as well as conforming 
to relevant product safety directives in the EU. CE marking is mandatory, but 
only applies to products that are covered by the subject matter of one or more 
of the New Approach Directives. We aim to clarify the process for obtaining a CE 
mark. MethOds: Published reviews, our experience and government and industry 
records were used to outline the complexities of this process, including how to 
determine the relevant type of classification and the steps that need to be taken to 
gain a CE Mark. Results: Medical devices fall into three categories, each of which 
are governed by a different EU directive: Directive of Active Implantable Medical 
Devices (90/385/EEC), Medical Devices Directive (93/42/EEC), and Directive of in Vitro 
Diagnostic Medical Devices (98/79/EC). Each one will encompass guidelines relating 
to an individual product and whether it is required to bear a CE mark. Once a CE 
Mark has been obtained a ‘declaration of conformity’ must be signed before you 
can place the CE mark on your product. This states that the manufacturer takes 
sole responsibility for the conformity within all the legal requirements to achieve 
a CE mark. CE marking means that the product can be marketed anywhere in the 
EU. cOnclusiOns: A CE mark states that a product has been assessed before being 
placed on the market and satisfies legislative requirements of the applicable EC 
directives. It ensures that a product has ‘free-movement’ within the EU as well as 
permitting the ‘withdrawal of products’, which do not conform. More and more 
products are required to have a CE mark if they want to gain access to EU market.
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Objectives: Robust literature demonstrates the clinical value of low-intensity 
pulsed ultrasound (LIPUS) in the treatment of fresh bone fractures. However, each 
published study used an arbitrary time post-fracture to define a “fresh fracture” for 
study inclusion. In the absence of an accepted clinical definition of fresh fracture, 
many third-party payers have adopted study inclusion criteria as de facto defini-
tions of fresh fracture. Yet exclusion of older fractures may deny access to patients 
who could benefit from LIPUS. We pooled data from patients in a post-market LIPUS 
registry required by the Food & Drug Administration to analyze the inflection point 
at which fracture heal rates begin to decline. MethOds: Patients are evaluated if the 
following data are known: days to LIPUS treatment; days on LIPUS treatment; and 
outcome of treatment (Heal / Fail). We present data from 7,117 patients treated with 
LIPUS within 365 days of fracture. We plot (Heal rate) vs. (Days to LIPUS treatment), 
to determine the inflection point at which Heal rate begins to decline. Results: 
Heal rate (Number of patients healed / Number of patients treated) did not differ 
significantly or clinically for at least 10 weeks following fracture. In 284 fracture 
patients who began LIPUS within 1 week of fracture, the heal rate was 97.2% (276 
healed / 284 treated). In 246 patients who began LIPUS treatment 10 weeks after 
fracture, the heal rate was 97.6% (240 healed / 246 treated). There may be a decrease 
in heal rate after 10 weeks, but the heal rate for patients at week 12 was 95.6% (195 
healed / 204 treated). cOnclusiOns: Heal rate with LIPUS was ~97% for ≤ 10 weeks 
following fracture. Many patients who could benefit may be unnecessarily excluded 
from treatment by payer guidelines. We will evaluate heal rate bone-by-bone (tibia, 
femur, humerus, radius, metatarsal) using this method.
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Objectives: Firstly, to identify what proportion of medical technologies notified to 
the National Institute for Health and Care Excellence’s (NICE) Medical Technologies 
Appraisal Committee (MTAC) are selected for evaluation by the MTEP. Secondly, to 
analyse the MTEP Committee’s interpretation of claimed healthcare system benefits 
and identify the influence of these benefits on decision-making. MethOds: The 
NICE website was used to identify: technologies considered by the MTAC up to May 
2015; the routing information for each technology; the healthcare system benefit 
claims and decision data for all technologies routed to the MTEP. The healthcare 
system benefit claims were categorised according to criteria listed in the NICE MTEP 
methods guide to facilitate identification of any association between the type of 
benefit claimed and the decision outcome. The decision-making committee’s con-
clusions on the claimed healthcare system benefits were interpreted. Results: 
By May 2015, the MTAC at NICE had considered 157 products, of which 99 were not 
selected for evaluation. Of the 58 products selected for evaluation, 35 were routed to 
the MTEP. Seventy-one per cent of MTEP decisions endorsed technology adoption. 
There have been instances of claimed health system benefits being accepted by 
